Welcome to our dedicated page for Medicure SEC filings (Ticker: MCUJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicure Inc. filings document a Canadian foreign private issuer that furnishes Form 6-K reports to the SEC while operating a U.S.-focused pharmaceutical and healthcare products business. The filings include press releases, management discussion and analysis, and condensed consolidated interim financial statements related to Medicure Pharma, AGGRASTAT, ZYPITAMAG, pharmacy operations, and research and development activity.
The company’s regulatory reports also provide formal disclosure of periodic operating results, product and pharmacy revenue categories, governance matters, and current corporate events. As a Form 20-F filer, Medicure’s SEC record centers on furnished foreign-issuer reports under Exchange Act Rule 13a-16 or 15d-16.
Medicure Inc. files its Form 20-F annual report, outlining a Canada-based specialty pharma business focused on cardiovascular drugs and U.S. pharmacy operations. As of December 31, 2025, it had 10,436,313 common shares outstanding and reports in Canadian dollars, with US $1.00 equal to CND $1.3706.
Revenue is concentrated in AGGRASTAT, which still contributed about 20% of total revenue, alongside ZYPITAMAG and three U.S. pharmacies (Marley Drug, Gateway Pharmacy, West Olympia Pharmacy). ZYPITAMAG generated US $6.5 million in 2024 revenue, slightly above the prior year, but uptake remains slower than expected in a highly competitive statin market.
The filing emphasizes extensive risk factors: intense competition and generic pressure on AGGRASTAT and ZYPITAMAG, reliance on third-party manufacturers, heavy regulation of pharmaceuticals and pharmacies, product liability exposure, environmental and workplace compliance, foreign-exchange risk from U.S.-dollar revenues, potential need for additional capital, share-price volatility, possible PFIC-related U.S. tax issues, and financial impact from U.S. policy changes under the Inflation Reduction Act, including assessed penalties.